Table 1.
Characteristics of Studies Included in the Meta-Analysis
| First authors, year | Diagnostic tool | Topiramate | Placebo | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Age (years),mean ± SD | Gender (male:female,%) |
Dose& Duration | Side effects/Adverse events | N | Age (years),mean ± SD | Gender (male: female,%) | |||
| Titration | Maintenance | |||||||||
| Paul Winner,2005 | International Headache Society (IHS) diagnostic criteria for pediatric migraine | 108 | 11.3 ± 2.5 | 50.9:49.1 | 8-week: Week 1 = 15 mg/d Week 2 = 30 mg/d Week 3 = 50 mg/d (dose increased to 2–3 mg/kg/d) |
12-week: 2–3 mg/kg/d | upper respiratory tract infection, anorexia, weight decrease, gastroenteritis, paresthesia, somnolence | 49 | 10.7 ± 2.6 | 53.1:46.9 |
| C. V. S. Lakshmi,2007 | International Classification of Headache Disorders, 2nd Edition (ICHD-II) | 21 | 10.95 ± 1.53 | 85.7:14.3 | 1-month: 25-mg incremented to 100 mg/d | 3-month: 100 mg/d | weight loss, lack of concentration in school, parasthesia, sedation, loss of appetite, pain in abdomen | 21 | 10.14 ± 1.35 | 52.4:47.6 |
| Donald Lewis,2009 | International Classification of Headache Disorders, 2nd Edition (ICHD-II) | 70† | 14.2 ± 1.54 | 40:60 | 4-week: 25-mg incremented to 50 or 100 mg/d† | 12-week: 50 or 100 mg/d | upper respiratory tract infection, paresthesia, abdominal pain, anorexia, injury, rhinitis, coughing, viral infection, pharyngitis, fatigue, nausea, dizziness, taste perversion, insomnia, back pain, conjunctivitis, sinusitis, asthma, pneumonia, fever, allergy, vomiting, nervousness, somnolence, abnormal vision, eye pain | 33 | 14.4 ± 1.7 | 36:64 |
| Scott W.Powers,2017a | International Classification of Headache Disorders, 2nd Edition (ICHD-II) | 145 | 14.2 ± 2.5 | 30:70 | 8-week: 2 mg/Kg.d, dose escalation occurred every 2 weeks | 16-week: average 1.93 ± 0.40 mg mg/Kg.d | aphasia, cognitive disorder, dizziness, memory impairment, paresthesia, general: fatigue, dry mouth, intussusception, streptococcal pharyngitis, upper respiratory tract infection, altered mood, suicide attempt, investigations: decreased weight, contusion, traumatic liver injury, respiratory: bronchospasm | 33 | 14.2 ± 2.2 | 32:68 |
SD standard deviations, N Total number in group
aThe analysis population included patients who ended trial early
†35 subjects treated with topiramate at 50 mg/day, 35 subjects treated with topiramate at 100 mg/day